University Hospitals

Axuall, Inc. is a workforce intelligence company headquartered in Cleveland, Ohio, that provides a digital network for verifying identity, credentials, and authenticity across various sectors, including healthcare, insurance, and logistics. Established in 2018, Axuall focuses on enhancing workforce analytics through a real-time practitioner data network, enabling healthcare systems, staffing firms, and telehealth organizations to streamline processes such as onboarding, credentialing, and enrollment. The company's integrated platform facilitates smarter decision-making and reduces the time required to onboard healthcare providers. By empowering professionals with control over their career identity, Axuall offers unique insights for network planning and analytics, ultimately driving efficiencies and maximizing revenue for its clients.

STAQ Pharma, Inc. is a Denver-based company that specializes in the manufacture and sale of compounded pharmaceutical medications. Initially known as QualMed Pharmacy, Inc., the company rebranded in 2018 and operates a cGMP-compliant outsourcing facility. STAQ Pharma produces a wide range of compounded medications, including non-sterile and sterile solutions, as well as repackaged sterile medications in prefilled syringes for hospital procedures. The company emphasizes safety, quality, and transparency in its operations, utilizing inventory systems to forecast demand and ensure timely availability of critical products for healthcare facilities. STAQ Pharma aims to enhance access to high-quality compounded medications through its online store and in-house production capabilities.

Babyscripts is a developer of a virtual maternity care platform aimed at enhancing prenatal and postpartum care for pregnant mothers. The company's three-tiered approach allows healthcare providers to deliver tailored, risk-specific care anytime and anywhere. The first tier features a mobile app that offers daily educational content and resources throughout pregnancy and the postpartum period. The second tier incorporates remote monitoring through medical devices, enabling patients to track health metrics like blood pressure and alerting providers to potential risks. This system facilitates the transition of care beyond traditional clinical settings, enabling providers to focus on higher-risk patients while automating routine care. The third tier fosters collaboration between care teams and insurers, addressing challenges in care coordination and access, ultimately improving health outcomes and reducing costs. Through its innovative platform, Babyscripts aims to eliminate maternal mortality and enhance access to quality care for all mothers.

BioMotiv is a therapeutic accelerator established in 2012 and headquartered in Cleveland, Ohio. It focuses on developing a portfolio of novel medicines as part of The Harrington Project for Discovery and Development, a significant initiative aimed at transforming the drug advancement process. Launched by University Hospitals, this $250 million project aims to align the research capabilities of the Harrington Discovery Institute with the development efforts of BioMotiv, thereby accelerating the innovation of therapeutics for the benefit of patients worldwide. BioMotiv primarily invests in companies within the healthcare and life sciences sectors, supporting advancements that promise to deliver breakthrough drugs to market more efficiently.

BioMotiv is a therapeutic accelerator established in 2012 and headquartered in Cleveland, Ohio. It focuses on developing a portfolio of novel medicines as part of The Harrington Project for Discovery and Development, a significant initiative aimed at transforming the drug advancement process. Launched by University Hospitals, this $250 million project aims to align the research capabilities of the Harrington Discovery Institute with the development efforts of BioMotiv, thereby accelerating the innovation of therapeutics for the benefit of patients worldwide. BioMotiv primarily invests in companies within the healthcare and life sciences sectors, supporting advancements that promise to deliver breakthrough drugs to market more efficiently.